MedTrace Logo

Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism

NCT00800358 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2012-12-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether oral paricalcitol is safer and more efficacious compared to oral calcitriol in the treatment of hyperparathyroidism in chronic kidney disease patients undergoing dialysis.

Conditions

Interventions

DRUG

Paricalitol

oral paricalcitol variable daily dosing based on intact PTH level for 6 months

DRUG

Calcitriol

oral calcitriol variable daily dosing based on intact PTH level for 6 months

Sponsors & Collaborators

  • Ministry of Health, Malaysia

    collaborator OTHER_GOV

  • Penang Hospital, Malaysia

    lead OTHER_GOV

Principal Investigators

  • Ong L Meng, MBBS, MRCP · Clinical Research Centre, Penang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-10-31
Completion
2009-12-31

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00800358 on ClinicalTrials.gov